With the incidence and prevalence of cardiovascular disease (CVD) increasing worldwide and its connection to chronic kidney disease (CKD), the new president of the European Renal Association – European Dialysis and Transplant Association outlined in a news conference at the association’s 48th Congress in Prague several steps by which physicians can help to alleviate the personal and economic burdens of CVD. CVD is responsible for about 10 percent of all illness and 30 percent of all deaths in the world.
Raymond Vanholder, MD, PhD, professor of medicine at the University of Ghent and clinical head of the nephrology division of the Ghent University Hospital in Belgium, said the most prominent risk factors for CVD are type 2 diabetes, hypertension, hypercholesterolemia, smoking, and overweight. Among other negative outcomes, obesity often leads to hypertension and disturbances in blood glucose and lipid metabolism. Besides poor diet, other unhealthy lifestyle factors such as physical inactivity, stress, alcohol consumption, and smoking increase the risk of CVD.
While the connection between CKD and CVD has been recognized only fairly recently, Vanholder made the point that it is significant and unmistakable. Even minor renal dysfunction confers a significantly greater risk of CVD, and a published community-based population study (Go AS et al. N Engl J Med. 2004; 351:1296–1305) on more than one million people with a mean age of 52 years has shown an independent association between a rising glomerular filtration rate (GFR) and mortality, cardiovascular events, and hospitalizations.
At the extreme end of the spectrum—people with end-stage renal disease on hemodialysis – the mortality risk may be hundreds-fold higher compared to the general public. Vanholder showed data that patients on dialysis aged 25 to 34 years have 375-fold higher risk of death compared with their healthy counterparts. The elevated risk compared to the general population decreases for older groups but is still significant. “Even for people 75 to 84 years old, which is people who have not much to go anymore, even there the mortality risk is five times higher in the patients on hemodialysis,” Vanholder showed.
For people who started on dialysis as children, their coronary artery calcification scores, a marker of atherosclerosis, remained fairly low until age 20 years but then increased exponentially. By age 30, “they show a calcification pattern that is worse than in normal people of age 80 or 90,” he said. (See Goodman WG et al. N Engl J Med. 2000; 342(20):1478–83). For patients who underwent follow-up measurements, their calcification scores nearly doubled over a mean period of 20 months.
Next he showed that the age-adjusted risk of death from any cause is directly related to the GFR. With a GFR of 60 mL/min/1.73 m2 or greater, the risk of death was 0.76/100 person-years. At a GFR of 45–59, essentially a loss of at least half one’s kidney function, the rate rose to 1.08/100 person-years. But as the GFR dropped below 45, the death rates rose precipitously, and with a GFR below 15, the death rate was 14.14/100 person-years.
Vanholder noted that dialysis is begun with a GFR below 15, so the increased risk of death persists for years even before dialysis is initiated. His own work has shown that mortality risk begins to increase as the GFR drops below 75 mL/min/1.73 m2.
“The big problem is that these people do not feel bad… and some people appear [at the nephrologist] only at the moment they need dialysis,” he said. “So screening is really something which is very necessary.” Estimates are that at least 10 percent of the global population has a GFR of 60 mL/min/1.73 m2 or below. Most will die before they ever reach the stage of dialysis.